Core Insights - QT Imaging Holdings, Inc. has announced a strategic collaboration with Intelerad Medical Systems to enhance breast health management through innovative imaging technology [1] Company Overview - QT Imaging is focused on transforming breast health management with radiation-free imaging technology [1] - Intelerad Medical Systems is recognized as a global leader in medical imaging solutions [1] Strategic Collaboration - The agreement involves the deployment of InteleShare Research picture archiving and communication systems (PACS) and Cloud PACS [1]

Core Thesis - PACS Group, Inc. is viewed positively due to its strong operational metrics, structural demand for post-acute care, and potential for significant stock price appreciation as regulatory uncertainties are resolved [1][5]. Company Overview - PACS Group, Inc. operates a network of 316 skilled nursing and assisted living facilities across the U.S., managing over 32,000 skilled nursing beds and 2,400 assisted living beds, serving nearly 30,000 patients daily [2]. - The company maintains an overall occupancy rate of 88.9%, with mature facilities achieving 95.1%, indicating strong demand and operational efficiency [2]. Quality and Performance - Approximately 65% of PACS facilities hold 4- or 5-star CMS ratings, reflecting high-quality performance [3]. - The company has experienced delays in SEC filings but has secured multiple NYSE extensions through November 19, 2025, indicating regulatory confidence in its progress [3]. Financial Health - PACS has resolved technical defaults with lenders through forbearance, demonstrating lender recognition of the company's long-term viability [4]. - The company has strengthened its leadership team and increased cash balances to $294 million, providing ample liquidity for operations and growth [4]. Market Position - PACS's stock is currently trading near $12, significantly below analyst targets of $30+, suggesting a mispricing due to past short-seller claims and filing delays rather than operational weaknesses [4]. - Compared to peers like $ENSG, which trade at higher valuations, PACS is considered undervalued, presenting a high-upside opportunity for equity investors [5]. Future Outlook - With expected clearance of filings, strong preliminary operating results, and strategic safeguards in place, PACS is positioned for sustained growth and potential re-rating to $20–30 per share or more [5].

Company Overview - PACS Group, Inc. is a leading post-acute care provider operating 316 facilities across 17 states, with over 32,000 skilled nursing beds and 2,400 assisted living beds, focusing on quality care [2] - The company has expanded rapidly since Q2 2024, adding 96 facilities to its portfolio [2] Financial Performance - As of June 30, PACS reported an occupancy rate of 88.9%, significantly higher than the industry average of 78% [3] - The company has cash reserves of $294.2 million, nearly double the levels at the end of 2024 [3] - Management projects record revenue and adjusted EBITDA for the first half of 2025 once financial filings are complete [3] Regulatory and Governance Issues - The New York Stock Exchange extended PACS's trading period to November 19, 2025, allowing more time for the company to complete financial restatements and SEC filings [3] - PACS is cooperating with an independent Audit Committee investigation into past financial matters [3] - Leadership changes occurred with the resignation of CFO Derick Apt after an internal policy investigation, and a former CFO has been appointed as interim [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving PACS Group, Inc. and its officers or directors [1] Group 1: Company Developments - On September 8, 2025, PACS announced the resignation of Chief Financial Officer Derick Apt due to allegations of accepting high-value items from associated individuals, which violated company policies [3] - Following the announcement of the CFO's resignation, PACS's stock price dropped by $3.29 per share, a decline of 29.08%, closing at $8.03 per share on September 9, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving PACS Group, Inc. and its officers or directors [1]. Group 1: Company Developments - On September 8, 2025, PACS announced the resignation of Chief Financial Officer Derick Apt due to allegations of accepting high-value items from associated individuals, which violated company policies [2]. - Following the announcement of the CFO's resignation, PACS's stock price dropped by $3.29 per share, representing a decline of 29.08%, closing at $8.03 per share on September 9, 2025 [2]. Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Group 1 - PACS Group, Inc. shares increased by 24.5% to $9.6, following a significant trading volume, contrasting with a 32.8% loss over the past four weeks [1][2] - The price surge was driven by investor optimism due to the announcement of four preliminary key operating metrics expected for the six months ending June 30, 2025, indicating solid business momentum [2] - The company anticipates quarterly earnings of $0.47 per share, reflecting a year-over-year increase of 771.4%, with revenues projected at $1.11 billion, up 12.8% from the previous year [3] Group 2 - The consensus EPS estimate for PACS has remained unchanged over the last 30 days, suggesting that stock price increases may not sustain without earnings estimate revisions [4] - PACS Group, Inc. holds a Zacks Rank of 3 (Hold), indicating a neutral outlook within the Zacks Medical Services industry [4] - Cencora, another company in the same industry, has a consensus EPS estimate of $3.84, representing a 15% increase from the previous year, and also holds a Zacks Rank of 3 (Hold) [5]

[FORM 8-K Filing Details](index=1&type=section&id=FORM%208-K%20Filing%20Details) This section details the Form 8-K filing, covering registrant information, securities registration, and general filing specifics [Registrant and Filing Information](index=1&type=section&id=Registrant%20and%20Filing%20Information) This section provides the administrative details of the Form 8-K filing, including the registrant's identity, incorporation state, address, and the report's filing date - Registrant: **PACS GROUP, INC.**, incorporated in Delaware[1](index=1&type=chunk) - Filing Date: **September 11, 2025**[1](index=1&type=chunk) - Registrant's principal executive offices: **262 N. University Ave., Farmington, Utah 84025**[1](index=1&type=chunk) [Securities Registration](index=1&type=section&id=Securities%20Registration) This part details the company's registered securities, their trading symbol, and the exchange on which they are listed, also indicating that the registrant is not an emerging growth company Securities Registration Details | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.001 par value per share | PACS | The New York Stock Exchange | - The registrant is not an emerging growth company[3](index=3&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section reports the announcement of preliminary operating metrics and clarifies the filing status and associated liabilities [Announcement of Preliminary Operating Metrics](index=2&type=section&id=Announcement%20of%20Preliminary%20Operating%20Metrics) PACS Group, Inc. issued a press release on September 11, 2025, announcing select unaudited preliminary operating metrics, which is furnished as Exhibit 99.1 to this Form 8-K - On **September 11, 2025**, PACS Group, Inc. issued a press release[4](index=4&type=chunk) - The press release announced select unaudited preliminary operating metrics[4](index=4&type=chunk) - A copy of the press release is furnished as **Exhibit 99.1** to this Current Report on Form 8-K[4](index=4&type=chunk) [Filing Status and Liabilities Disclaimer](index=2&type=section&id=Filing%20Status%20and%20Liabilities%20Disclaimer) This section clarifies that the information in this Form 8-K, including Exhibit 99.1, is furnished and not considered 'filed' for Section 18 liability purposes of the Exchange Act, nor is it automatically incorporated by reference into other filings - The information in this Form 8-K (including Exhibit 99.1) shall not be deemed 'filed' for purposes of **Section 18 of the Securities Exchange Act of 1934**[5](index=5&type=chunk) - It is not subject to the liabilities of that section[5](index=5&type=chunk) - It shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference[5](index=5&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the financial statements and exhibits included in the Form 8-K filing [Exhibits List](index=2&type=section&id=Exhibits%20List) This section provides a table listing the exhibits accompanying the Form 8-K filing, specifically the press release and the interactive data file Form 8-K Exhibits | Exhibit No. | Description | | :---------- | :---------- | | 99.1 | Press Release of the Company dated September 11, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [SIGNATURES](index=3&type=section&id=SIGNATURES) This section formally concludes the report with the authorized signature and date [Execution of Report](index=3&type=section&id=Execution%20of%20Report) This section formally concludes the report, confirming its execution on behalf of PACS Group, Inc. by its Chief Executive Officer - The report was duly caused to be signed on behalf of **PACS GROUP, INC.**[8](index=8&type=chunk)[9](index=9&type=chunk) - Signed by **Jason Murray**, Chief Executive Officer[10](index=10&type=chunk) - Date of signature: **September 11, 2025**[10](index=10&type=chunk)

Core Points - PACS Group, Inc. has been granted an additional trading period by the NYSE until November 19, 2025, to facilitate the completion of its financial statement restatement [1] Group 1 - The NYSE Listing Operations Committee approved the extension on September 9, 2025, allowing PACS more time for its ongoing review [1] - The additional trading period is crucial for PACS to address the previously announced restatement of its financial statements [1]

Company Overview - PACS Group, Inc. shares increased by 21.8% to close at $12.35, with trading volume significantly higher than usual, contrasting with a 6.2% loss over the past four weeks [1] - The company is undergoing an audit committee investigation, which is nearly complete, and no integrity issues have been found regarding top management [2] Financial Performance - PACS Group is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year increase of 10.5%, with revenues projected at $1.09 billion, up 16.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - PACS Group operates within the Zacks Medical Services industry, where Sotera Health Company, a peer, has seen a 3.3% decline in its stock price recently and a negative return of 11.6% over the past month [4] - Sotera Health's consensus EPS estimate has also remained unchanged, currently at $0.17, which is a decrease of 10.5% compared to the previous year [5]

Core Insights - Konica Minolta Healthcare Americas, Inc. has launched the next-generation Exa® Platform, featuring the most advanced version of Exa PACS|RIS to date, which includes a new API platform for integration with strategic partners [1] - The new Exa PACS|RIS version introduces Exa Advanced Imaging with enhanced Multi Planar Reconstruction (MPR) and full 3D image reconstruction capabilities, streamlining clinician workflows [1][4] - The Exa PAC|RIS ecosystem includes NewVue, an AI-powered radiologist worklist, Clearpath Technologies' automated record-sharing platform, and Quinsite's Comprehensive Healthcare Analytics Platform™ for data-driven decision-making [3] Company Overview - Konica Minolta Healthcare is a leading provider in medical diagnostic imaging and healthcare IT, focusing on transforming primary imaging technologies to enhance diagnostic capabilities [5] - The company has a legacy of 150 years in innovation, evolving from a camera and film manufacturer to a strategic partner in healthcare imaging solutions [6][7] - The recent launch of Exa Enterprise, an integrated PACS and Vendor Neutral Archive (VNA), complements the Exa PACS|RIS, providing comprehensive workflow and image viewing solutions across specialties [4]